Core Viewpoint - The company, 朝聚眼科 (stock code: 02219), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 120,000 shares [1] - The total expenditure for the buyback is HKD 319,200 [1] - The buyback price per share ranges from HKD 2.63 to HKD 2.70 [1]

Group 1 - The company, Chaoyue Eye Care (02219), announced a share buyback on December 4, 2025, for a total expenditure of HKD 319,200 [1] - The company repurchased 120,000 shares at a price range of HKD 2.63 to HKD 2.70 per share [1]

Core Viewpoint - The Shenzhen Stock Exchange organized a roadshow in Frankfurt to promote investment opportunities in China, focusing on high-quality economic development during the 14th Five-Year Plan period and enhancing understanding of the Shenzhen market among local investors [1] Group 1: Roadshow Activities - The roadshow aimed to showcase the investment value of Shenzhen-listed companies and the opportunities in the Chinese capital market, with 11 overseas roadshows conducted this year across various countries, including Germany [1] - Participating companies included Sungrow Power Supply, Weichai Power, Aier Eye Hospital, Robotech, and Hailiang Co., which are involved in digital economy, high-end manufacturing, and green low-carbon sectors [1][2] Group 2: Company Highlights - Sungrow Power Supply is leveraging the EU's "REPowerEU" strategy to capture green energy transition opportunities in Germany, focusing on high-performance photovoltaic inverters and energy storage systems [2] - Weichai Power's acquisition of KION Group has led to significant revenue growth, with KION's revenue increasing from 4 billion euros to over 10 billion euros, contributing approximately 40% to Weichai's income [2] - Robotech is set to acquire the leading German company ficonTEC to address domestic high-end equipment shortages in the photonics sector, enhancing the self-sufficiency of the photonics device industry [2] Group 3: Market Insights - Investors noted the effective collaboration between Chinese and German companies, driven by technological capabilities and market demand, presenting vast investment opportunities [2][3] - Chinese companies are diversifying their export markets and enhancing operational resilience through solid supply chain strategies, with overseas revenue for Weichai expected to exceed 100 billion yuan in 2024 [3] Group 4: ESG Practices - Shenzhen-listed companies are increasingly focusing on ESG practices, gaining recognition from German long-term investors [4][5] - Companies like Sungrow and Weichai are integrating ESG principles into their strategic planning, with Aier Eye Hospital achieving an MSCI ESG rating upgrade to A [5] Group 5: Future Outlook - The event highlighted a growing interest from German investors in China's market, shifting focus from cost advantages to technology innovation and supply chain collaboration [6] - The Shenzhen Stock Exchange plans to enhance services for foreign investors and facilitate cross-border financing activities to support domestic and international economic circulation [6]

Group 1 - The Shenzhen Stock Exchange announced a periodic adjustment of sample stocks for various indices, including the Shenzhen Component Index and the ChiNext Index, effective December 15, 2025 [1] - Huaxia Eye Hospital (301267) is one of the stocks being removed from the ChiNext Index sample list [1] Group 2 - Huaxia Eye Hospital was listed on the ChiNext on November 7, 2022, with an initial offering price of 50.88 RMB per share and is currently in a state of decline [2] - The total funds raised from the initial public offering amounted to 305.28 million RMB, with a net amount of 276.85 million RMB after deducting issuance costs [2] - The company originally planned to raise 77.85 million RMB for various projects, including hospital construction and operational upgrades, but ultimately raised 198.99 million RMB more than planned [2] Group 3 - In the 2022 annual shareholders' meeting held on May 15, 2023, the company approved a profit distribution plan, distributing a cash dividend of 2.8 RMB per 10 shares, totaling 15.68 million RMB [3] - The company also approved a capital reserve increase, converting 5 shares for every 10 shares held, increasing the total share capital from 56 million shares to 84 million shares [3] - Huaxia Eye Hospital Group was established in 2004 in Xiamen, Fujian Province, with a registered capital of 84 million RMB [3]

Financial Data and Key Metrics Changes - The company is focused on achieving financial excellence, particularly improving EBITDA margins to align with or exceed competitors [4][5] - A three-year plan was announced, targeting a revenue growth rate of 5%-7% and a consistent margin improvement of approximately 200 basis points per year [12][56] Business Line Data and Key Metrics Changes - The Vision 27 program aims to enhance operational excellence and gross margins, with thousands of employees involved in various projects [5][7] - The contact lens market is experiencing a slowdown, with growth around 4%, but the company is growing faster than the market [23][24] Market Data and Key Metrics Changes - The company noted a slowdown in the Asian markets, particularly in China, which is affecting overall growth [23][24] - The bifurcation in consumer spending is evident, with lower-end consumers feeling more financial pressure compared to middle and high-income consumers [24] Company Strategy and Development Direction - The company is prioritizing organic growth over M&A, with a focus on enhancing its existing pipeline and improving its balance sheet [15][16] - Innovation is a key focus, with new products like Project Halo aimed at addressing significant consumer issues in the contact lens market [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve its targets, citing recent sales growth and margin improvements as indicators of progress [10][56] - The company is optimistic about the future, expecting to see continued growth and innovation leading to a stronger market position [5][10] Other Important Information - The company is committed to improving its liquidity and addressing its ownership structure, which is currently 88% owned by Bausch Health [11] - The pipeline is projected to generate over $7 billion in potential revenue, highlighting significant growth opportunities [54] Q&A Session Summary Question: What components contributed to the 5%-7% revenue long-range plan? - Management acknowledged the difficulty in predicting future performance but expressed confidence in their balanced guidance based on current market conditions [12][13] Question: How does the company view tuck-in M&A? - The company currently does not require M&A for its three-year plan, focusing instead on organic growth and improving its balance sheet [15][16] Question: What is the expected timeline for new product launches? - The company anticipates launching new products, including a bioactive contact lens, by 2028, with clinical studies ongoing [19][22] Question: How is the company managing its R&D budget? - The company is increasing its R&D budget to approximately 7.5% of revenue, focusing on programs that promise the best returns [36][38] Question: What is the outlook for the dry eye market? - Management believes they have the best portfolio for treating dry eye, with Xiidra and Miebo positioned as leading products in the market [40][41]

Financial Data and Key Metrics Changes - The company is focused on achieving financial excellence, particularly improving EBITDA margins to align with or exceed competitors [5][6][11] - A three-year plan was announced, targeting a revenue growth rate of 5%-7% [13][15] - The company aims for a net leverage of 3.5 times by 2028 [18] Business Line Data and Key Metrics Changes - The Vision 27 program is designed to enhance operational efficiency and gross margins across various business lines [6][11] - The contact lens segment is expected to grow faster than the market, with a new bioactive platform, Project Halo, set to launch in 2028 [21][27] - The dry eye product portfolio, including Xiidra and Miebo, is positioned as the gold standard in the market [52] Market Data and Key Metrics Changes - The contact lens market has slowed to about 4% growth, influenced by economic conditions in Asia, particularly China [28][29] - The company anticipates a recovery in the contact lens market, projecting growth to return to 5% or higher by 2026 [29] Company Strategy and Development Direction - The company is committed to organic growth, with no M&A planned in the three-year strategy [18] - Focus on innovation is critical, with a deep pipeline of products expected to drive future growth [90] - The company aims to leverage its existing infrastructure for new product launches to maintain high margins [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation into a high-performance competitor, emphasizing the importance of innovation and operational excellence [5][6] - The management highlighted the need for a disciplined approach to spending as growth resumes [9][11] - The company is optimistic about the aging population's demand for premium IOLs, viewing it as a growth driver [89] Other Important Information - The company is focusing on enhancing its R&D efficiency, aiming to allocate more resources towards product development rather than administrative costs [50] - The introduction of new products like Lumify Luxe and the expansion of the PreserVision brand are seen as significant growth opportunities [44][46] Q&A Session Summary Question: How should investors think about the liquidity of Bausch + Lomb given its ownership structure? - Management acknowledged the 88% ownership by Bausch Health and indicated that both boards are committed to addressing liquidity issues, though the timeline is uncertain [12] Question: What are the components of the 5%-7% revenue long-range plan? - Management explained that the guidance is based on current market conditions and internal capabilities, with a balanced approach to growth [13][15] Question: How does the company view tuck-in M&A opportunities? - Management stated that no M&A is needed at this time, focusing instead on organic growth and improving the balance sheet [18] Question: What is the expected timeline for the new bioactive contact lens material? - The new product is expected to launch in 2028, with ongoing clinical studies providing positive data [24][27] Question: How does the company plan to manage its R&D budget? - The company is increasing its R&D spending to about 7.5% of revenue, focusing on high-potential programs [48][50] Question: What is the outlook for the dry eye market? - Management believes they have the best portfolio for dry eye treatment, with Xiidra and Miebo positioned as leading products [52] Question: What is the growth outlook for the surgical business? - The surgical business is expected to grow steadily, driven by an aging population and consistent demand for IOLs [89]

Group 1 - The core point of the article is that Aier Eye Hospital has disclosed its total number of shareholders, which is 344,788 as of September 30, 2025 [2]

证券日报网讯 12月3日，何氏眼科在互动平台回答投资者提问时表示，目前，公司部分下属门店已引入 雷鸟创新智能眼镜产品进行销售，并为相关用户提供配套的专业验光服务。该合作系基于市场需求的常 规业务布局，对公司财务状况及经营成果未构成重大影响。未来，若双方合作涉及重大事项达到信息披 露标准，公司将严格按照监管要求及时履行信息披露义务，敬请投资者理性投资。 （文章来源：证券日报） ...

Core Viewpoint - The company is closely monitoring the integration of technological innovation with healthcare, particularly the potential applications of smart and augmented reality technologies in ophthalmic medical scenarios [1] Summary by Relevant Categories Company Developments - He Shi Eye Hospital (301103) has indicated its commitment to observing advancements in technology and healthcare integration [1] - The company will fulfill its information disclosure obligations in accordance with regulatory requirements if there are significant developments or if it meets disclosure standards [1] Industry Trends - There is a growing interest in the application of smart and augmented reality technologies within the ophthalmology sector, highlighting a trend towards technological integration in medical practices [1]

Group 1 - The core viewpoint of the article is that He Shi Eye Hospital has initiated a business collaboration with Thunderbird Innovation, focusing on the sale of smart glasses and providing professional optical services to users [1] - The collaboration is based on regular business layout driven by market demand and does not significantly impact the company's financial status or operational results [1] - The company commits to timely information disclosure if any significant matters arise from the collaboration that meet disclosure standards [1]